WordPress database error: [Table './shroom/wp_clean_up_optimizer_ip_locations' is marked as crashed and last (automatic?) repair failed]
SELECT * FROM wp_clean_up_optimizer_ip_locations WHERE ip='3.238.180.174'

Mind Cure Health Inc. – Shroom Investor 🍄

Mind Cure Health Inc.

Mind Cure Health Inc.

MINDCURE Announces Strategic Review

Independent Special Committee Formed VANCOUVER, BC, Feb. 10, 2022 - Mind Cure Health Inc. (CSE: MCUR) (OTCQX: MCURF) (FRA: 6MH) ("MINDCURE"), a leader in advanced proprietary technology for mental health care and research in psychedelics, announced today its Board of Directors has formed a special committee (the "Special Committee") of in... Read More...

MINDCURE Hires Dr. Clare Purvis from Headspace to the position of Chief Product Officer to Advance Mental Health Digital Therapeutics Platform

VANCOUVER, BC, Feb. 3, 2022 - Mind Cure Health Inc. (CSE: MCUR) (OTCQX: MCURF) (FRA: 6MH) ("MINDCURE"), a leader in advanced proprietary technology for mental health care and research in psychedelics, announced today the hiring of Dr. Clare Purvis, formerly Headspace Inc.'s Vice President of Clinical Product and Content Development, for t... Read More...

MINDCURE Announces Certification of HIPAA Compliance, Bringing iSTRYM Closer to Commercial Deployment in the Second Quarter of 2022

VANCOUVER, BC, Dec. 16, 2021 - Mind Cure Health Inc. (CSE: MCUR) (OTCQX: MCURF) (FRA: 6MH) ("MINDCURE"), a leader in advanced proprietary technology and research for psychedelics, announced today that the Company and its digital therapeutics technology, iSTRYM, have been certified as Health Insurance Portability and Accountability Act (HI... Read More...

MINDCURE Provides Update on Studies and Clinical Trials

VANCOUVER, BC, Nov. 4, 2021 - Mind Cure Health Inc. (CSE: MCUR) (OTCQX: MCURF) (FRA: 6MH) ("MINDCURE"), a leader in advanced proprietary technology and research for psychedelics, is pleased to provide an operational progress update on the strategic initiatives of its operating segments - MINDCURE Research and MINDCURE Technology. MINDCURE... Read More...

MINDCURE Signs LOI with Awakn Life Sciences to Distribute Ketamine Protocol for Alcohol Use Disorder into Clinics Across United States and Canada through iSTRYM, MINDCURE’s Digital Therapeutics Platform

VANCOUVER, BC, Oct. 28, 2021 - Mind Cure Health Inc. (CSE: MCUR) (OTCQX: MCURF) (FRA: 6MH) ("MINDCURE"), a leader in advanced proprietary technology and research for psychedelics, is pleased to announce the signing of a non-binding letter of intent ("LOI") with Awakn Life Sciences (NEO: AWKN)(OTCQB: AWKNF) ("Awakn"), a biotechnology compa... Read More...

MINDCURE Announces Financial Results for the First Quarter of Fiscal 2022

VANCOUVER, BC, Oct. 26, 2021 - Mind Cure Health Inc. (CSE: MCUR) (OTCQX: MCURF) (FRA: 6MH) ("MINDCURE"), a leader in advanced proprietary technology and research for psychedelics, today announced its financial results for the three months ended August 31, 2021.  All amounts are stated in Canadian dollars unless otherwise indicated.   Q1 F... Read More...

MINDCURE Launches “Desire Project” To Treat Female Hypoactive Sexual Desire Disorder With MDMA-Assisted Psychotherapy

First-of-its-kind study targets a female sexual disorder affecting an estimated 9.5 million women in the U.S. alone VANCOUVER, BC, Sept. 27, 2021 - Mind Cure Health Inc. (CSE: MCUR) (OTCQB: MCURF) (FRA: 6MH) ("MINDCURE"), a leader in advanced proprietary technology and research in psychedelics, introduces its "Desire Project," a clinical ... Read More...

MINDCURE Signs Exclusive Digital Clinical Data Licensing Agreement with ATMA Journey Centers

MINDCURE to utilize patient data provided by ATMA to optimize iSTRYM, its digital therapeutics platform VANCOUVER, BC, Sept. 23, 2021 - Mind Cure Health Inc. (CSE: MCUR) (OTCQB: MCURF) (FRA: 6MH) ("MINDCURE" or the "Company"), a leader in advanced proprietary technology and research in psychedelics, announced today an exclusive data licen... Read More...

MINDCURE to Participate in Maxim Group LLC’s Advances in Mental Health Virtual Conference

VANCOUVER, BC, Sept. 17 , 2021 - Mind Cure Health Inc. (CSE: MCUR) (OTCQB: MCURF) (FRA: 6MH) ("MINDCURE"), a leader in advanced proprietary technology and research in psychedelics, today announced that Kelsey Ramsden, President & CEO of MINDCURE, will participate in two panel sessions at the Advances in Mental Health Virtual Conferenc... Read More...

MINDCURE Joins Digital Therapeutics Alliance to Drive Innovation in the Mental Health Industry

VANCOUVER, BC, Sept. 16, 2021 - Mind Cure Health Inc. (CSE: MCUR) (OTCQB: MCURF) (FRA: 6MH) ("MINDCURE"), a leader in advanced proprietary technology and research in psychedelics, announced today it's joining the Digital Therapeutics Alliance, a non-profit association of industry leaders with a mission to drive awareness and adoption of d... Read More...

MINDCURE to Present at the H.C. Wainwright 23rd Annual Global Investment Conference

VANCOUVER, BC, Sept. 8, 2021 - Mind Cure Health Inc. (CSE: MCUR) (OTCQB: MCURF) (FRA: 6MH) ("MINDCURE"), a leader in advanced proprietary technology and research in psychedelics, today announced that Kelsey Ramsden, President & CEO of MINDCURE, will present at the H.C. Wainwright 23rd Annual Global Investment Conference being held fro... Read More...

MINDCURE Reaches Milestone, Releasing First of its Kind Mental Health Digital Therapeutics Platform to Partner Clinics in North America

With its minimum viable product (MVP) release on schedule and on budget, MINDCURE will work with its clinical partners to refine the application before full commercial deployment in Q1 2022. VANCOUVER, BC, Aug. 26, 2021 - Mind Cure Health Inc. (CSE: MCUR) (OTCQB: MCURF) (FRA: 6MH) ("MINDCURE"), a leader in advanced proprietary technology ... Read More...

MINDCURE Welcomes Dr. Ken Weingardt, Digital Therapy Visionary, as a Senior Clinical Technology Advisor to its Psychedelic Digital Therapeutics Team

Dr. Weingardt, a clinical psychologist and previously a Senior Clinical Director at Pear Therapeutics will guide MINDCURE's digital therapeutics technology (DTx) platform, iSTRYM, through near-term commercial deployment VANCOUVER, BC, Aug. 10, 2021 - Mind Cure Health Inc. (CSE: MCUR) (OTCQB: MCURF) (FRA: 6MH) ("MINDCURE"), a leader in adv... Read More...

MINDCURE Appoints Jerry White, Award-Winning Humanitarian Activist Who Shares in the 1997 Nobel Peace Prize, as Company Advisor

The recipient of numerous human rights and leadership awards, Mr. White will assist MINDCURE on its mission to revolutionize mental health treatments through the development and scaling of science-backed psychedelic medicines globally. VANCOUVER, BC, Aug. 4, 2021 - Mind Cure Health Inc. (CSE: MCUR) (OTCQB: MCURF) (FRA: 6MH) ("MINDCURE"), ... Read More...

MINDCURE Launches Second Stage of Manufacturing Synthetic Ibogaine for Use in Psychedelic Clinical Research

MINDCURE's pharmaceutical grade ibogaine would provide researchers access to a sustainable, high-quality, reliable, and consistent supply of the psychedelic drug. VANCOUVER, BC, July 27, 2021 - Mind Cure Health Inc. (CSE: MCUR) (OTCQB: MCURF) (FRA: 6MH) ("MINDCURE"), a leader in advanced proprietary technology and research for psychedelic... Read More...

MINDCURE Announces Filing of U.S. Provisional Patent Applications for Company’s First Fully Synthetic Routes to Create an Ibogaine Psychedelic Compound

The company's pharmaceutical grade ibogaine would provide researchers access to a sustainable, high-quality, reliable, and consistent supply of the psychedelic drug, ibogaine. VANCOUVER, BC, July 13, 2021 - Mind Cure Health Inc. (CSE: MCUR) (OTCQB: MCURF) (FRA: 6MH) ("MINDCURE" or the "Company"), a leader in advanced proprietary technolo... Read More...

MINDCURE Adopts Advance Notice Policy

VANCOUVER, BC, July 12, 2021 - Mind Cure Health Inc. (CSE: MCUR) (OTCQB: MCURF) (FRA: 6MH) ("MINDCURE" or the "Company"), a leader in advanced proprietary technology and research for psychedelics, is pleased to announce that the Company's board of directors (the "Board") has adopted a policy that requires advance notice to the Company wit... Read More...

Maxim Group Initiates Coverage of Mind Cure Health

VANCOUVER, BC, June 30, 2021 - Mind Cure Health Inc. (CSE: MCUR) (OTCQB: MCURF) (FRA: 6MH) ("MINDCURE" or the "Company"), a leader in advanced proprietary technology and research for psychedelics, is pleased to announce that Maxim Group analysts Jason McCarthy and Michael Okunewitch initiated coverage on MINDCURE. About Mind Cure Health I... Read More...

MINDCURE Develops Proprietary Ketamine-Enhanced Psychotherapy Protocols for Treatment of Pain and Depression

MINDCURE will distribute these protocols to therapists through iSTRYM, its digital therapeutics platform. This milestone in protocol development unlocks the company's protocol distribution platform in time for iSTRYM's clinical MVP launch in Q3 2021. VANCOUVER, BC, June 17, 2021 - Mind Cure Health Inc. (CSE: MCUR) (OTCQB: MCURF) (FRA: 6MH... Read More...

MINDCURE Successfully Completes First Stage of Manufacturing Synthetic Ibogaine for Use in Psychedelic Clinical Research

By manufacturing ibogaine, MINDCURE's research team will have access to a predictable and standardized supply of synthetic ibogaine while ensuring consistent dosing and reliable results. VANCOUVER, BC, June 3, 2021 - Mind Cure Health Inc. (CSE: MCUR) (OTCQB: MCURF) (FRA: 6MH) ("MINDCURE" or the "Company"), a leader in advanced proprietary... Read More...

Dr. Joel Raskin, a leader in psychiatry and neuroscience drug development, joins MINDCURE as Chief Medical Officer

Dr. Raskin is a psychiatrist and academic with 20 years of international pharmaceutical experience in neuroscience drug development, lifecycle preparation, launch, and commercialization VANCOUVER, BC, May 20, 2021 - Mind Cure Health Inc. (CSE: MCUR) (OTCQB: MCURF) (FRA: 6MH) ("MINDCURE" or the "Company"), a leader in advanced proprietary ... Read More...